 | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | IndoVac |
| Routes of administration | Intramuscular |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
IndoVac is arecombinantprotein subunitCOVID-19 vaccine,[1][2] developed byIndonesian pharmaceutical companyBio Farma andBaylor College of Medicine inHouston, Texas.[1][2] It is the world's first officiallyhalal certified COVID-19 vaccine,[3] but the most popular existing vaccines had already been widely endorsed as Halal by various Islamic groups.[4][5] The vaccine was officially launched by PresidentJoko Widodo on 13 October 2022.[6]
The vaccine consists of an active yeast-basedreceptor binding domain (RBD) of theSARS‑CoV‑2spike protein.[7] With no animal cells or products being used in its production,[3] IndoVac received its halal certificate from the Halal Product Assurance Organizing Body of theMinistry of Religious Affairs on 29 July 2022.[8]
In October 2022, President Joko Widodo announced that Bio Farma will produce up to 20 million doses of the vaccine for the initial first phase of production in the same year. The production capacity will be increased to 40 million doses in 2023.[1]
| Locations | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Response | |||||||||
| Institutions |
| ||||||||
| People |
| ||||||||
| Timeline | |||||||||
| Data (templates) | |||||||||
